Interview Guidance Program (IGP) for UPSC CSE 2024, Registrations Open Click Here to know more and registration
News: WHO has endorsed a new class of drug, GLP-1 Receptor Agonists, for managing obesity.
About GLP-1 Receptor Agonists
- Role: They mimic a hormone that regulates appetite and blood sugar level, lipid metabolism, and other biological functions.
- Drugs in this class include semaglutide and tirzepatide, which have potential to be transformative.
- Utility:
- Helps in treatment of Type 2 diabetes and obesity.
- These drugs can complement current policies promoting healthy eating and physical exercise to curb the obesity pandemic.
- These drugs are significant as obesity affects nearly 1 in 8 people worldwide.
- Side Effects: There are severe side effects like stomach paralysis, inflamed pancreas and thyroid cancer.
Discover more from Free UPSC IAS Preparation Syllabus and Materials For Aspirants
Subscribe to get the latest posts sent to your email.
